FGF21 and chronic kidney disease: Moreover, by inhibiting the expression of CDK1, regulating the cell cycle, slowing down mitotic catastrophe, and reducing the loss of podocytes and eventually alleviating proteinuria caused by glomerular filtration barrier damage in diabetic nephropathic mice, FGF21 is expected to become a promising therapeutic drug to reduce podocyte loss and improve the prospect of chronic kidney disease.